BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35241534)

  • 1. A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England.
    Mokbel K; Daniels R; Weedon MN; Jackson L
    In Vivo; 2022; 36(2):780-800. PubMed ID: 35241534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Under-reporting of gastrointestinal bleeding associated with anticoagulant use using the UK Yellow Card Scheme.
    Shuttleworth P; Baker J; Clark E
    Int J Clin Pharm; 2023 Aug; 45(4):1014-1018. PubMed ID: 37269441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review.
    Inch J; Watson MC; Anakwe-Umeh S
    Drug Saf; 2012 Oct; 35(10):807-18. PubMed ID: 22928729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge, attitude, practice and barriers towards pharmacovigilance and adverse drug reactions reporting among healthcare professionals in Turkey: a systematic review.
    Khan Z; Karatas Y; Martins MAP; Jamshed S; Rahman H
    Curr Med Res Opin; 2022 Jan; 38(1):145-154. PubMed ID: 34694167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.
    Klein K; Hazell L; Stolk P; Shakir S
    Drug Saf; 2020 Mar; 43(3):255-263. PubMed ID: 31872358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK.
    Thompson A; Randall C; Howard J; Barker C; Bowden D; Mooney P; Munyika A; Smith S; Pirmohamed M
    J Clin Pharm Ther; 2019 Feb; 44(1):78-83. PubMed ID: 30206951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
    Rehan HS; Chopra D; Holani SN; Mishra R
    Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
    O' Donovan B; Rodgers RM; Cox AR; Krska J
    Br J Clin Pharmacol; 2022 Jul; 88(7):3434-3446. PubMed ID: 35128732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
    Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
    Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK.
    de Vries ST; Denig P; Andrić A; Dimov Di Giusti M; Ptaszynska-Neophytou A; Härmark L; Mol PGM;
    Drug Saf; 2021 Oct; 44(10):1073-1083. PubMed ID: 34368940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal.
    Ribeiro-Vaz I; Santos C; da Costa-Pereira A; Cruz-Correia R
    Drug Saf; 2012 May; 35(5):387-94. PubMed ID: 22468615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with spontaneous adverse drug reaction reporting among healthcare professionals in Vietnam.
    Le TT; Nguyen TTH; Nguyen C; Tran NH; Tran LA; Nguyen TB; Nguyen N; Nguyen HA
    J Clin Pharm Ther; 2020 Feb; 45(1):122-127. PubMed ID: 31486525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reactions of analgesic medicines: analysis of the Romanian pharmacovigilance database.
    Cazacu I; Stroe R; Dondera R; Mogosan C; Haramburu F; Fourrier-Réglat A; Loghin F
    Fundam Clin Pharmacol; 2018 Jun; 32(3):330-336. PubMed ID: 29314262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of spontaneous reporting of adverse drug reactions within primary care: the paradox of low prescribers who are high reporters.
    Cox AR; Anton C; McDowell SE; Marriott JF; Ferner RE
    Br J Clin Pharmacol; 2010 May; 69(5):529-34. PubMed ID: 20573089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.